Development of a Novel Anti-Mouse CCR2 Monoclonal Antibody (C2Mab-6) by N-Terminal Peptide Immunization

  • Monoclon Antib Immunodiagn Immunother. 2022 Apr;41(2):80-86. doi: 10.1089/mab.2021.0063.
Tomohiro Tanaka  1 ,  Guanjie Li  2 ,  Teizo Asano  1 ,  Masaki Saito  2 ,  Mika K Kaneko  1 ,  Hiroyuki Suzuki  2 ,  Yukinari Kato  1  2
Affiliations
  • 1. Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • 2. Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan.
PMID: 35377242 DOI: 10.1089/mab.2021.0063
Abstract

The CC Chemokine Receptor type-2 (CCR2) belongs to the G-protein-coupled receptor superfamily, expressed on the cell surface of immune cells and tumors. CCR2 binds to the CC motif chemokine 2/monocyte chemoattractant protein-1, a CC chemokine, which is produced by various cells, including immune-related cells and tumors. Therefore, the development of sensitive monoclonal antibodies (mAbs) for CCR2 has been desired for treatment and diagnosis. This study established a novel, specific, and sensitive anti-mouse CCR2 (mCCR2) mAb; C2Mab-6 (rat IgG1, kappa), using the mCCR2 synthetic peptide immunization method. C2Mab-6 reacted with mCCR2-overexpressed Chinese hamster ovary-K1 cells and L1210 (murine leukemia) cells, which express endogenous mCCR2 in flow cytometry. Furthermore, C2Mab-6 showed a high binding affinity for both cells. Hence, C2Mab-6 can be a useful tool for analyzing mCCR2-related biological responses, using flow cytometry.

Keywords
CCR2; flow cytometry; monoclonal antibody.
Products